Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that two abstracts evaluating INS50589, Inspire’s reversible P2Y12 receptor antagonist targeted for use in acute cardiac care, were presented in poster sessions at the American College of Cardiology’s 55th Annual Scientific Session, held March 11-14, 2006 at the Georgia World Congress Center in Atlanta, Georgia.
